Jeanne M. Palmer, MD

Articles

Myeloproliferative Neoplasm Management: Future Directions in Care

February 2nd 2023

Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.

Sequencing and Managing Combination Therapy in Myeloproliferative Neoplasms

January 26th 2023

Following their overview on novel treatment modalities in myeloproliferative neoplasms, expert panelists consider how best to sequence and manage novel therapies in practice.

An Expanding Armamentarium in MPNs: Therapeutic Strategies Under Investigation

January 26th 2023

A broad and comprehensive review of novel targeted agents under investigation in the setting of myeloproliferative neoplasm management.

Myeloproliferative Neoplasms: Targeting CALR With Novel Therapy

January 19th 2023

Key opinion leaders on myeloproliferative neoplasms review the potential of CALR as a therapeutic target following data from the ASH 2022 Annual Meeting.

What is the Role of Transplant in Managing Patients With Myelofibrosis?

January 19th 2023

Expert panelists consider the ongoing role of transplant for patients with myelofibrosis and discuss when it is more appropriate to explore systemic therapy options.

Therapy in Myelofibrosis: Fedratinib and Ruxolitinib Strategies

January 12th 2023

Closing out their discussion on the management of myelofibrosis, panelists highlight updated data with fedratinib and ruxolitinib, respectively.

Myelofibrosis: Nuancing the Potential of Disease Modification

January 12th 2023

A brief review of the biology of myelofibrosis, the potential for disease modification, and subsequent implications for treatment.

Therapy in Myelofibrosis: Pacritinib

January 5th 2023

Key opinion leaders on myeloproliferative neoplasms review clinical data behind pacritinib therapy in the setting of myelofibrosis.

Novel Therapy in Myelofibrosis: Momelotinib

January 5th 2023

Switching their focus to myelofibrosis management, expert panelists reflect on clinical data behind momelotinib, a novel JAK2 inhibitor.

Role of Symptom Burden in Thrombocythemia and Polycythemia Vera

December 22nd 2022

Shared insight on how a patient’s symptom burden can impact management strategies within essential thrombocytopenia and polycythemia vera.

Overview on Essential Thrombocythemia and Polycythemia Vera Management

December 22nd 2022

Expert perspectives on the respective treatment landscapes of essential thrombocytopenia (ET) and polycythemia vera (PV) following the ASH 2022 Annual Meeting.

Dr. Palmer on Symptom Burden in Myelofibrosis With Thrombocytopenia

December 19th 2022

Jeanne M. Palmer, MD, discusses total symptom scores in patients with myelofibrosis with thrombocytopenia.

The Future of Myeloproliferative Neoplasm Treatment

August 24th 2022

The panelists conclude their discussion by highlighting investigational agents to look forward to.

Clinical Scenario: A 74-Year-Old with Cytopenic Myelofibrosis

August 24th 2022

Rami Komrokji, MD, presents to the panel a second clinical scenario of a 74-year-old with cytopenic myelofibrosis.

Myelofibrosis Treatment Approaches after Disease Progression

August 18th 2022

A look at the potential treatment options for a patient with myelofibrosis who progresses after first-line therapy.

Clinical Scenario: A 67-Year-Old with Myelofibrosis

August 18th 2022

Key opinion leaders discuss how they would approach treating a 67-year-old with myelofibrosis, presenting with splenomegaly.

Management of Accelerated Phase Myeloproliferative Neoplasms

August 11th 2022

Drs Palmer and Mesa explain the challenges of treating accelerated phase myeloproliferative neoplasms.

Novel Agents Under Investigation for Myelofibrosis

August 11th 2022

The panel reviews other exciting novel agents under investigation for myelofibrosis treatment.

Momelotinib in Myelofibrosis Treatment: Updates from ASCO 2022

August 11th 2022

Ruben Mesa, MD, discusses updates on the novel agent momelotinib from an abstract he presented at ASCO 2022.

Efficacy and Safety of JAK Inhibitors for Myelofibrosis

August 11th 2022

Jamile Shammo, MD, FACP, explains the efficacy and safety of the 3 approved therapies for myelofibrosis.